Results 21 to 30 of about 28,236 (118)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins

Acta Pharmaceutica Sinica B, 2014
Dipeptidyl peptidase 4 (DPP4) is recognised as an attractive anti-diabetic drug target, and several DPP4 inhibitors are already on the market. As members of the same gene family, dipeptidyl peptidase 8 (DPP8) and dipeptidyl peptidase 9 (DPP9) share high ...
Jinglong Liu, Yi Huan, Caina Li, Minzhi Liu, Zhufang Shen   +4 more
doaj   +1 more source

Sex Differences in Cardiovascular Effectiveness of Newer Glucose‐Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Randomized controlled trials showed that newer glucose‐lowering agents are cardioprotective, but most participants were men. It is unknown whether benefits are similar in women.
Valeria Raparelli, Malik Elharram, Cristiano S. Moura, Michal Abrahamowicz, Sasha Bernatsky, Hassan Behlouli, Louise Pilote   +6 more
doaj   +1 more source

The effect of Islamic fasting in Ramadan on osteoporosis [PDF]

Journal of Fasting and Health, 2017
Osteoporosis is considered as one of the most common diseases that women face after their menopause and is caused by both genetic and environmental factors.
Seyed Mohammad Amin Kormi, Shima Ardehkhani, Mohammad Amin Kerachian   +2 more
doaj   +1 more source

Cardioprotective effects of sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase 4 inhibitor in type 2 diabetes: A meta-analysis of comparative safety and efficacy

SAGE Open Medicine
Background: Sodium glucose cotransporter 2 inhibitors are recommended for the treatment of heart failure due to their cardioprotective effects, despite primarily being used as antidiabetic medications. However, the comparative profile of two antidiabetic
Abhigan Babu Shrestha, Anupam Halder, Kripa Rajak, Saroj Kumar Jha, Ramesh Lamichhane, Arefin Naher Oishee, Nayanika Tummala Chowdary, Pashupati Pokharel, Sajina Shrestha, Lukash Adhikari, Bikash Adhikari, Aman Rajak, Jalal Haider Khan, Nischal Mainali   +13 more
doaj   +1 more source

PERsonalised Medicine for Intensification of Treatment (PERMIT) in type 2 diabetes mellitus: a target trial emulation from routine data

Health Technology Assessment
Background Evidence is required on the relative effectiveness of sulphonylureas, dipeptidyl peptidase-4 inhibitors or sodium–glucose cotransporter 2 inhibitors added to metformin for people with type 2 diabetes mellitus.
David G Lugo-Palacios, Patrick Bidulka, Paul Charlton, Bill Huston, Anna Carnegie, Orlagh Carroll, Stephen O’Neill, Amanda I Adler, Anirban Basu, Richard J Silverwood, Andrew H Briggs, Liam Smeeth, Ian J Douglas, Kamlesh Khunti, Richard Grieve   +14 more
doaj   +1 more source

Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review

Терапевтический архив
The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group.
Iuliia G. Samoilova, Olga E. Vaizova, Anastasia E. Stankova, Mariia V. Matveeva, Daria V. Podchinenova, Dmitry A. Kudlay, Anastasiia A. Borozinets, Tatyana A. Filippova, Ivan R. Grishkevich, Anastasia V. Partala, Diana A. Gerasimova   +10 more
doaj   +1 more source

Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease

Cardiovascular Diabetology, 2012
Background Diabetic patients present with an accelerated atherosclerotic process and an increased risk for future cardiovascular events. In addition to the risk imposed by the disease itself, pharmacological treatment adds also a sizable risk, especially
Klempfner Robert, Leor Jonathan, Tenenbaum Alexander, Fisman Enrique Z, Goldenberg Ilan   +4 more
doaj   +1 more source

Inhibitors of dipeptidyl-peptidase-4: obvious and probable (literature review)

Медицинский совет, 2022
The purpose of the presented literature review was an attempt to sum up current estimates of the effect of the use of dipeptidyl peptidase-4 inhibitors (iDPP-4) in the algorithms of both traditional (diabetes mellitus) and a number of alternative ...
E. A. Ortenberg, L. A. Suplotova
doaj   +1 more source

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report

Medicine Science, 2018
Vildagliptin is a new generation theurapeutic agent of diabetes mellitus which belongs to dipeptidyl peptidase-IV inhibitor class acting via the incretin hormone system.
Serhat Sayin, Ethem Omeroglu, Semra Aslan Bilgin   +2 more
doaj   +1 more source

Teneligliptin-induced polyarthritis: A case report

Journal of Diabetology, 2021
Rationale: DPP4 inhibitors are very important armamentarium for the management of type 2 diabetes mellitus. Usually, dipeptidyl peptidase-4 (DDP-4) inhibitors are free from side effects.
Prabhat Kumar Agrawal, Nikhil Pursnani, Ashish Gautam, Boentika Singh, Asvini Yadav   +4 more
doaj   +1 more source